BC Innovations | Jan 29, 2015
Distillery Therapeutics

Therapeutics: EPH receptor A2 (EPHA2); BRAF

Cancer INDICATION: Melanoma Cell culture, mouse and patient studies suggest inhibiting EPHA2 could help treat melanoma that is resistant to the BRAF inhibitor Zelboraf vemurafenib. In metastatic lesions from melanoma patients on Zelboraf therapy, EPHA2...
Items per page:
1 - 1 of 1